Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VB15010 Tablets in Patients with Advanced Solid Tumors
Latest Information Update: 18 Feb 2025
At a glance
- Drugs VB 15010 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shenzhen Yangli Pharmaceutical Technology
Most Recent Events
- 18 Feb 2025 New trial record